[A17-38] Carfilzomib (multiple myeloma) – Benefit assessment according to §35a Social Code Book V
Last updated 15.11.2017
Project no.:
A17-38
Commission:
Commission awarded on 15.08.2017 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adult patients with multiple myeloma who have received at least one previous treatment
Combination with lenalidomide and dexamethasone: for patients < 65 years hint of non-quantifiable added benefit. An added benefit is not proven for patients ≥ 65 years. Combination with dexamethasone: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A18-04 | Carfilzomib (multiple myeloma) - Addendum to Commission A17-38 | Commission completed |
| G15-16 | Carfilzomib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V | Commission completed |
| G16-11 | Carfilzomib (multiple myeloma; combination with dexamethasone alone) – Assessment according to § 35a (para. 1, sentence 10) Social Code Book V | Commission completed |
| A21-08 | Carfilzomib (multiple myeloma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2018-02-15 A G-BA decision was published.